Abstract
High-dose-rate (HDR) brachytherapy is an established curative treatment option for patients diagnosed with prostate cancer. In contrast to low-dose-rate (LDR) brachytherapy, that involves the permanent implant of several radioactive seeds in the prostate, HDR uses a single, high-intensity radioactive source of 192Iridium which is sent and retracted sequentially into each of the needles (or catheters) temporarily implanted in the gland. Advances in mechanical and planning systems and in computer technology result in a sophisticated treatment technique that reliably delivers a very high-quality radiation dose distribution to the target in a very short period of time while minimizing the irradiation of the surrounding critical organs. Several advantages over other radiotherapy techniques have been identified, namely, (1) the accurate positioning of the sources by first implanting nonactive guide needles, (2) the possibility to exactly choose the position of the source over the entire length of every single needle, (3) the absence of any target movement during irradiation, (4) the possibility of “online” adjustments of dwell source locations according to 3-D planning based on individual dose prescription, (5) the absence of any need for preimplant needles preparation, and finally (6) a safer radioprotection profile as compared to permanent seeds implant procedure. HDR brachytherapy is generally proposed in combination with external beam irradiation for patients having intermediate- to high-risk cancers, but protocols have been recently developed in order to use it as monotherapy for low-risk cases. In this chapter, the rational, indications, technique, and clinical results (both in terms of efficacy and toxicity) of HDR brachytherapy for prostate cancer will be presented and discussed. Finally, some future directions together with critical issues regarding this technique will be addressed.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Ares C, PopowskiY PS et al (2009) Hypofractionated boost with high-dose-rate brachytherapy and open magnetic resonance imaging-guided implants for locally aggressive prostate cancer: a sequential dose-escalation pilot study. Int J Radiat Oncol Biol Phys 75:656–673
Arruda-Viani GA, Pellizzon AC, Guimaraes FS et al (2009) High dose rate and external beam radiotherapy in locally advanced prostate cancer. Am J Clin Oncol 32:187–190
Astrom L, Pedersen D, Mercke C et al (2005) Long-term outcome of high dose rate brachytherapy in radiotherapy of localized prostate cancer. Radiother Oncol 74:157–161
Barry MJ, Fowler FJ, O’Leary MP et al (1992) Measurement committee of the American Urological Association. The American Urological Association symptom index for benign prostatic hyperplasia. J Urol 148:1549–1557
Brenner DJ, Martinez A, Edmundson GK et al (2002) Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late responding normal tissue. Int J Radiat Oncol Biol Phys 52:6–13
Cahlon O, Zelefsky MJ, Shippy A et al (2008) Ultra high dose, 86.4 Gy, IMRT for localized prostate cancer: toxicity and biochemical outcomes. Int J Radiat Oncol Biol Phys 71:330–337
Corner C, Rojas AM, Bryant L et al (2008) A phase II study of high-dose-rate afterloading brachytherapy as monotherapy for the treatment of localized prostate cancer. Int J Radiat Oncol Biol Phys 72:441–446
Cornud F, Flam T, Chauveinc L et al (2002) Extraprostatic spread of clinically localized prostate cancer: factors predictive of pT3 tumors and of MR imaging examination results. Radiology 224:203–210
Crook J (2011) The role of brachytherapy in the definitive management of prostate cancer. Cancer Radiother 15:230–237
Crook J, McLean M, Catton C et al (2002) Factors influencing risk of acute urinary retention after TRUS-guided permanent prostate seed implantation. Int J Radiat Oncol Biol Phys 52:453–460
De Crevoisier R, Tucker SL, Dong L et al (2005) Increased risk of biochemical and local failure in patients with distended rectum on the planning CT for prostate cancer radiotherapy. Int J Radiat Oncol Biol Phys 62:965–973
Dearnaley DP, Sydes MR, Graham JD et al (2007) Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RTO1 randomised trial. Lancet Oncol 6:475–487
Demanes DJ, Rodriguez RR, Schour L et al (2005) High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California Endocurietherapy’s 10 year results. Int J Radiat Oncol Biol Phys 61:1306–1316
Demanes DJ, Martinez A, Ghilezan M et al. (2011) High-dose-rate monotherapy: safe and effective brachytherapy for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys 81:1286–1292
Deutsch I, Zelefsky MJ, Zhang Z et al (2010) Comparison of PSA relapse-free survival in patients treated with ultra-high-dose IMRT versus combination HDR brachytherapy and IMRT. Brachytherapy 9:313–318
Duchesne GM, Williams SG, Das R et al (2007) Patterns of toxicity following high-dose-rate brachytherapy boost for prostate cancer: mature prospective phase I-II study results. Radiother Oncol 84:128–134
Edmundson GK, Di Yan RT, Martinez A et al (1995) Intraoperative optimization of needle placement and dwell times for conformal prostate brachytherapy. Int J Radiat Oncol Biol Phys 33:1257–1263
Foster W, Cunha JAM, Chow-Hsu I et al (2011) Dosimetric impact of catheters interfractions movement in high dose rate prostate brachytherapy. Int J Radiat Oncol Biol Phys 80:85–90
Fuchsjager M, Shukla-Dave A, Akin O et al (2008) Prostate cancer imaging. Acta Radiol 49:107–120
Galalae RM, Kovacs G, Schultze J et al (2002) Long-term outcome after elective irradiation of the pelvic lymphatics and local dose escalation using high dose rate brachytherapy for locally advanced prostate cancer. Int J Radiat Oncol Biol Phys 52:81–90
Galalae RM, Martinez A, Nuernberg N et al (2006) Hypofractionated conformal HDR brachytherapy in hormone naïve men with localized prostate cancer. Is escalation to very high biologically equivalent dose beneficial in all prognostic risk groups? Strahlenther Onkol 182:135–141
Ghadjar N, Keller T, Rentsch CA et al (2009) Toxicity and early treatment outcomes in low and intermediate-risk prostate cancer managed by high dose rate brachytherapy as a monotherapy. Brachytherapy 8:45–51
Heidenreich A, Bellmunt J, Bolla M et al (2011) EAU guidelines on prostate cancer. Part 1: screening, diagnosis and treatment of clinically localized disease. Eur Urol 59:61–71
Hermesse J, Biver S, Jansen N et al (2009) A dosimetric selectivity intercomparison of HDR brachytherapy, IMRT and helical tomotherapy in prostate cancer radiotherapy. Strahlenther Onkol 185:736–742
Hoskin P (2008) High dose rate brachytherapy for prostate cancer. Cancer Radiother 12:512–514
Hoskin P, Motohashi K, Bownes P et al (2007) High dose rate brachytherapy in combination with external beam radiotherapy in the radical treatment of prostate cancer: initial results of a randomized phase three trial. Radiat Oncol 84:114–120
Hsu IC, Bae K, Shinohara K et al (2010) Phase II trial of combined high-dose-rate brachytherapy and external beam radiotherapy for adenocarcinoma of the prostate: preliminary results of RTOG 0321. Int J Radiat Oncol Biol Phys 78:751–758
Joiner MC, Bentzen SM (2009) Fractionation: the linear-quadratic approach. In: Joiner MC, Van der Kogel A (eds) Basic clinical radiobiology, 4th edn. Hodder Arnold, London
Kalkner KM, Wahlgren T, Ryberg M et al (2007) Clinical outcome in patients with prostate cancer treated with external beam radiotherapy and high dos-rate iridium 192 brachytherapy boost: a 6 year follow-up. Acta Oncol 46:909–917
Kovacs G, Potter R, Loch T et al (2005) GEC/ESTRO-EAU recommendations on temporary brachytherapy using stepping sources for localized prostate cancer. Radiother Oncol 74:137–148
Krauss D, Kestin L, Ye H et al (2011) Lack of benefit for the addition of androgen deprivation therapy to dose-escalated radiotherapy in the treatment of intermediate- and high-dose prostate cancer. Int J Radiat Oncol Biol Phys 80:1064–1071
Lee B, Shinohara K, Weinberg V et al (2007) Feasibility of high-dose-rate brachytherapy salvage for local prostate cancer recurrence after radiotherapy: the University of California-San Francisco experience. Int J Radiat Oncol Biol Phys 67:1106–1112
Mark RJ, Anderson PJ, Akins RS et al (2010) Interstitial high-dose-rate brachytherapy as monotherapy for early stage prostate cancer: median 8 years results in 301 patients. Brachytherapy 9:s76
Martens C, Pond G, Webster D et al (2006) Relationship of the IPS score with urinary flow study, and catheterization rates following 125I prostate brachytherapy. Brachytherapy 5:9–13
Martinez A, Demanes J, Galalae R (2005a) High dose rate afterloading 192Ir prostate brachytherapy. In: Dicker AP, Merrick GS, Waterman FM et al (eds) Basics and advanced techniques in prostate brachytherapy. Taylor Francis Group, Abingdon
Martinez A, Demanes J, Galalae R (2005b) Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regimen. Int J Radiat Oncol Biol Phys 62:1322–1331
Martinez A, Demanes J, Vargas C et al (2010) High-dose-rate-prostate brachytherapy. An excellent accelerated-hypofractionated treatment for favorable prostate cancer. Am J Clin Oncol 33:481–488
Martinez A, Gonzalez J, Ye H et al (2011) Dose escalation improves cancer-related events at 10 years for intermediate- and high-risk prostate cancer patients treated with hypofractionated high-dose-rate boost and external beam radiotherapy. Int J Radiat Oncol Biol Phys 79:363–370
McGrath SD, Antonucci JV, Fitch DL et al (2010) PSA bounce after prostate brachytherapy with or without neoadjuvant androgen deprivation. Brachytherapy 9:137–144
Mohammed N, Kestin L, Ghilezan M et al. (2012) Comparison of acute and late toxicities for three modern high-dose radiation treatment techniques for localized prostate cancer. Int J Radiat Oncol Biol Phys 82:204–212
Morton GC, Loblaw DA, Sankreacha R et al (2010) Single-fraction High-Dose-Rate brachytherapy and hypofractionated external beam radiotherapy for men with intermediate-risk prostate cancer: analysis of short- and medium-term toxicity and quality of life. Int J Radiat Oncol Biol Phys 77:811–817
Neviani CB, Miziara MA, De Andrade CH (2011) Results of high dose-rate brachytherapy boost after 2D or 3D external beam irradiation for prostate cancer. Radiother Oncol 98:169–174
Nickers P, Thissen B, Jansen N et al (2006) 192Ir Or 125I prostate brachytherapy as a boost to external beam radiotherapy in locally advanced prostatic cancer: a dosimetric point of view. Radiother Oncol 78:47–52
Peeters ST, Heembergen WD, Koper PC et al (2006) Dose–response in radiotherapy for localized prostate cancer. Results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 24:1990–1996
Pieters BR, De Back DZ, Koning CCE et al (2009) Comparison of three radiotherapy modalities on biochemical control and overall survival for the treatment of prostate cancer: a systematic review. Radiother Oncol 93:168–173
Rogers CL, Alder SC, Rogers RL et al (2012) High dose brachytherapy as Monotherapy for Intermediate risk prostate cancer. J Urol 187:109–116
Rosen RC, Riley A, Wagner G et al (1997) The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 49:822–830
Seppenwoolde Y, Kolkman-Deurloo IK, Sipkema D et al (2008) HDR prostate monotherapy-dosimetric effects of implant deformation due to posture change between TRUS- and CT-imaging. Radiother Oncol 86:114–119
Simnor T, Li S, Lowe G et al (2009) Justification for inter-fraction correction of catheter movement in fractionated high dose-rate brachytherapy treatment of prostate cancer. Radiother Oncol 93:253–258
Slessinger ED (2010) Technical note practical consideration for prostate HDR brachytherapy. Brachytherapy 9:282–287
Stone NN, Marshall DT, Stone JJ et al (2010) Does neo-adjuvant hormonal therapy improve urinary function when given to men with large prostates undergoing prostate brachytherapy? J Urol 183:634–640
Sullivan L, Williams SG, Thai KH et al (2009) Urethral stricture following high dose rate brachytherapy for prostate cancer. Radiother Oncol 91:232–236
Tharp M, Hardacre M, Bennett R et al (2008) Prostate high-dose-rate brachytherapy as salvage treatment of local failure after previous external or permanent seed irradiation for prostate cancer. Brachytherapy 7:231–236
The International Prostate Symptom Score (I-PSS) and Quality of Life assessment (1991) Proceedings of the international consultation on benign prostatic hyperplasia (BPH), Paris, 280–281
Tiong A, Bydder S, Ebert M et al (2010) A small tolerance for catheters displacement in high dose rate prostate brachytherapy is necessary and feasible. Int J Radiat Oncol Biol Phys 76:1066–1072
Yoshioka Y, Konishi K, Sumida I et al (2011) Monotherapeutic high-dose-rate brachytherapy for prostate cancer: five years results of an extreme hypofractionation regimen with 54 Gy in nine fractions. Int J Radiat Oncol Biol Phys 80:469–475
Zaider M, Zelefsky M, Lee EK et al (2000) Treatment planning for prostate implants using magnetic-resonance spectroscopy imaging. Int J Radiat Oncol Biol Phys 47:1085–1096
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Bossi, A., Verstraet, R., Calmels, L., Blanchard, P. (2012). High-Dose-Rate Brachytherapy: Indications, Technique, and Results. In: Bolla, M., van Poppel, H. (eds) Management of Prostate Cancer. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-27597-5_11
Download citation
DOI: https://doi.org/10.1007/978-3-642-27597-5_11
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-27596-8
Online ISBN: 978-3-642-27597-5
eBook Packages: MedicineMedicine (R0)